

# Evanthia Galanis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1444132/publications.pdf>

Version: 2024-02-01

132  
papers

16,738  
citations

22132

59  
h-index

15716

125  
g-index

132  
all docs

132  
docs citations

132  
times ranked

16917  
citing authors

#	ARTICLE	IF	CITATIONS
1	Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group. <i>Journal of Clinical Oncology</i> , 2010, 28, 1963-1972.	0.8	3,222
2	Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 401.	3.8	1,225
3	Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC3): a multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1049-1060.	5.1	840
4	Phase II Trial of Temozolomide (CC-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	0.8	688
5	Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. <i>Neuro-Oncology</i> , 2020, 22, 1073-1113.	0.6	543
6	Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. <i>Neuro-Oncology</i> , 2018, 20, 184-191.	0.6	443
7	Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 101-117.	4.3	437
8	Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. <i>Neuro-Oncology</i> , 2015, 17, 1188-98.	0.6	346
9	Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 507-518.	12.5	332
10	Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 2052-2058.	0.8	323
11	Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. <i>Neuro-Oncology</i> , 2005, 7, 164-176.	0.6	296
12	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.0	289
13	Extrapulmonary small cell carcinoma. , 1997, 79, 1729-1736.		268
14	Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer. <i>Cancer Research</i> , 2010, 70, 875-882.	0.4	264
15	Intraperitoneal therapy of ovarian cancer using an engineered measles virus. <i>Cancer Research</i> , 2002, 62, 4656-62.	0.4	193
16	Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study. <i>Neuro-Oncology</i> , 2012, 14, 215-221.	0.6	189
17	Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1167-1174.	1.9	184
18	DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. <i>Neuro-Oncology</i> , 2019, 21, 901-910.	0.6	184

#	ARTICLE	IF	CITATIONS
19	Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model. <i>Clinical Cancer Research</i> , 2009, 15, 7246-7255.	3.2	176
20	Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. <i>Journal of Neurosurgery</i> , 1998, 89, 425-430.	0.9	161
21	Oncolytic Measles Virus Expressing the Sodium Iodide Symporter to Treat Drug-Resistant Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 22-30.	0.4	157
22	Vorinostat in solid and hematologic malignancies. <i>Journal of Hematology and Oncology</i> , 2009, 2, 31.	6.9	152
23	Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial. <i>Clinical Cancer Research</i> , 2013, 19, 4816-4823.	3.2	140
24	The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. <i>Neuro-Oncology</i> , 2017, 19, 625-635.	0.6	137
25	Phase II Trial of Intravenous CI-1042 in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 1498-1504.	0.8	136
26	Phase II Trial of Intravenous Administration of Reolysin <sup>®</sup> (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. <i>Molecular Therapy</i> , 2012, 20, 1998-2003.	3.7	135
27	Management of recurrent meningeal hemangiopericytoma. <i>Cancer</i> , 1998, 82, 1915-1920.	2.0	131
28	Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases. <i>Neuro-Oncology</i> , 2020, 22, 757-772.	0.6	131
29	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. <i>Neuro-Oncology</i> , 2015, 17, 1261-1269.	0.6	126
30	Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods <sup>1</sup> . <i>Neuro-Oncology</i> , 2006, 8, 156-165.	0.6	117
31	Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. <i>Neuro-Oncology</i> , 2019, 21, 26-36.	0.6	114
32	Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. <i>Journal of Clinical Oncology</i> , 2017, 35, 361-369.	0.8	109
33	Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. <i>Neuro-Oncology</i> , 2020, 22, 1262-1275.	0.6	109
34	Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. <i>Current Cancer Drug Targets</i> , 2018, 18, 177-187.	0.8	107
35	Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. <i>Critical Reviews in Oncology/Hematology</i> , 2001, 38, 177-192.	2.0	106
36	Optimizing patient derived mesenchymal stem cells as virus carriers for a Phase I clinical trial in ovarian cancer. <i>Journal of Translational Medicine</i> , 2013, 11, 20.	1.8	106

#	ARTICLE	IF	CITATIONS
37	Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience. <i>Journal of Clinical Oncology</i> , 1999, 17, 3313-3323.	0.8	105
38	Clinical trial end points for high-grade glioma: the evolving landscape. <i>Neuro-Oncology</i> , 2011, 13, 353-361.	0.6	105
39	Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. <i>Journal of Neuro-Oncology</i> , 2012, 108, 187-193.	1.4	103
40	Advances in multidisciplinary therapy for meningiomas. <i>Neuro-Oncology</i> , 2019, 21, i18-i31.	0.6	102
41	Retargeted Oncolytic Measles Strains Entering via the EGFRvIII Receptor Maintain Significant Antitumor Activity against Gliomas with Increased Tumor Specificity. <i>Cancer Research</i> , 2006, 66, 11840-11850.	0.4	101
42	Phase II trial of gemcitabine in advanced sarcomas. <i>Cancer</i> , 2002, 94, 3225-3229.	2.0	96
43	Use of Viral Fusogenic Membrane Glycoproteins as Novel Therapeutic Transgenes in Gliomas. <i>Human Gene Therapy</i> , 2001, 12, 811-821.	1.4	93
44	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	0.6	93
45	Engineered measles virus as a novel oncolytic therapy against prostate cancer. <i>Prostate</i> , 2009, 69, 82-91.	1.2	89
46	New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials. <i>Neuro-Oncology</i> , 2013, 15, 1568-1579.	0.6	88
47	A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. <i>Breast Cancer Research and Treatment</i> , 2006, 99, 177-184.	1.1	86
48	Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. <i>Neuro-Oncology</i> , 2017, 19, now179.	0.6	85
49	Epidermal Growth Factor Receptor (EGFR)-Retargeted Measles Virus Strains Effectively Target EGFR- or EGFRvIII Expressing Gliomas. <i>Molecular Therapy</i> , 2007, 15, 677-686.	3.7	84
50	Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 1123-1132.	3.0	83
51	Noninvasive Imaging and Radiovirotherapy of Prostate Cancer Using an Oncolytic Measles Virus Expressing the Sodium Iodide Symporter. <i>Molecular Therapy</i> , 2009, 17, 2041-2048.	3.7	82
52	Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme. <i>Clinical Cancer Research</i> , 2007, 13, 7155-7165.	3.2	80
53	Toxicology Study of Repeat Intracerebral Administration of a Measles Virus Derivative Producing Carcinoembryonic Antigen in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas. <i>Human Gene Therapy</i> , 2008, 19, 690-698.	1.4	80
54	Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. <i>Current Opinion in Molecular Therapeutics</i> , 2009, 11, 43-53.	2.8	79

#	ARTICLE	IF	CITATIONS
55	Interleukin-13 Displaying Retargeted Oncolytic Measles Virus Strains Have Significant Activity Against Gliomas With Improved Specificity. <i>Molecular Therapy</i> , 2008, 16, 1556-1564.	3.7	73
56	Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. <i>Breast Cancer Research and Treatment</i> , 2010, 122, 745-754.	1.1	71
57	North Central Cancer Treatment Group Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination With Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 468-475.	0.4	71
58	Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion. <i>PLoS ONE</i> , 2013, 8, e56505.	1.1	68
59	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. <i>Clinical Cancer Research</i> , 2022, 28, 594-602.	3.2	67
60	Oncolytic measles virus strains in the treatment of gliomas. <i>Expert Opinion on Biological Therapy</i> , 2008, 8, 213-220.	1.4	66
61	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	0.6	64
62	The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. <i>Clinical Cancer Research</i> , 2016, 22, 575-581.	3.2	62
63	Therapeutic Potential of Oncolytic Measles Virus: Promises and Challenges. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 88, 620-625.	2.3	60
64	Oncolytic measles virus strains as novel anticancer agents. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 483-502.	1.4	60
65	Treatment of medulloblastoma with a modified measles virus. <i>Neuro-Oncology</i> , 2010, 12, 1034-1042.	0.6	58
66	Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations. <i>Cancer</i> , 2019, 125, 2910-2914.	2.0	58
67	CODEL: phase III study of RT, RT+ TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. <i>Neuro-Oncology</i> , 2021, 23, 457-467.	0.6	58
68	PTEN Loss Does Not Predict for Response to RAD001 (Everolimus) in a Glioblastoma Orthotopic Xenograft Test Panel. <i>Clinical Cancer Research</i> , 2008, 14, 3993-4001.	3.2	55
69	A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells. <i>Virus Research</i> , 2019, 263, 145-150.	1.1	53
70	Biodistribution of Oncolytic Measles Virus After Intraperitoneal Administration into Ifnar $\alpha$ , $\beta$ -CD46 $\beta$ Transgenic Mice. <i>Human Gene Therapy</i> , 2003, 14, 1565-1577.	1.4	51
71	A phase 1 and randomized, placebo-controlled phase 2 trial of bevacizumab plus dasatinib in patients with recurrent glioblastoma: Alliance/North Central Cancer Treatment Group N0872. <i>Cancer</i> , 2019, 125, 3790-3800.	2.0	51
72	Dephosphorylation of HuR Protein during Alphavirus Infection Is Associated with HuR Relocalization to the Cytoplasm*. <i>Journal of Biological Chemistry</i> , 2012, 287, 36229-36238.	1.6	50

#	ARTICLE	IF	CITATIONS
73	Expression of Immunomodulatory Neutrophil-activating Protein of Helicobacter pylori Enhances the Antitumor Activity of Oncolytic Measles Virus. <i>Molecular Therapy</i> , 2012, 20, 1139-1147.	3.7	49
74	Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. <i>Lancet Oncology</i> , The, 2012, 13, e196-e204.	5.1	49
75	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	0.6	49
76	Recurrent papillary craniopharyngioma with BRAF V600E mutation treated with dabrafenib: case report. <i>Journal of Neurosurgery</i> , 2019, 130, 1299-1303.	0.9	49
77	Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. <i>Modern Pathology</i> , 2012, 25, 1333-1344.	2.9	48
78	Effective Radiovirotherapy for Malignant Gliomas by Using Oncolytic Measles Virus Strains Encoding the Sodium Iodide Symporter (MV-NIS). <i>Human Gene Therapy</i> , 2012, 23, 419-427.	1.4	48
79	Immunogenicity of attenuated measles virus engineered to express Helicobacter pylori neutrophil-activating protein. <i>Vaccine</i> , 2011, 29, 1710-1720.	1.7	47
80	Phase I Trial of a Pathotropic Retroviral Vector Expressing a Cytocidal Cyclin G1 Construct (Rexin-G) in Patients With Advanced Pancreatic Cancer. <i>Molecular Therapy</i> , 2008, 16, 979-984.	3.7	46
81	Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2003, 21, 3761-3769.	0.8	42
82	Potential and clinical translation of oncolytic measles viruses. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 353-363.	1.4	41
83	Phase 1/2 trial of temsirolimus and sorafenib in the treatment of patients with recurrent glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572. <i>Cancer</i> , 2018, 124, 1455-1463.	2.0	41
84	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
85	Phase 0 and window of opportunity clinical trial design in neuro-oncology: a RANO review. <i>Neuro-Oncology</i> , 2020, 22, 1568-1579.	0.6	38
86	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. <i>Neuro-Oncology</i> , 2022, 24, 855-871.	0.6	38
87	Barriers to accrual and enrollment in brain tumor trials. <i>Neuro-Oncology</i> , 2019, 21, 1100-1117.	0.6	36
88	Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. <i>Neuro-Oncology</i> , 2012, 14, 459-470.	0.6	35
89	Biosafety considerations for attenuated measles virus vectors used in virotherapy and vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 1102-1116.	1.4	35
90	Treatment of medulloblastoma using an oncolytic measles virus encoding the thyroidal sodium iodide symporter shows enhanced efficacy with radioiodine. <i>BMC Cancer</i> , 2012, 12, 508.	1.1	33

#	ARTICLE	IF	CITATIONS
91	Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1593-1607.	1.1	32
92	Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials. <i>Current Oncology Reports</i> , 2013, 15, 56-63.	1.8	32
93	Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results. <i>Journal of Neuro-Oncology</i> , 2009, 92, 165-175.	1.4	30
94	Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ER $\alpha$ Expression in Initially ER $\alpha$ + Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e96995.	1.1	30
95	High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. <i>Cancer</i> , 2008, 112, 1805-1811.	2.0	29
96	Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. <i>Cancer</i> , 2004, 101, 2557-2566.	2.0	28
97	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	0.6	28
98	Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. <i>Neuro-Oncology</i> , 2020, 22, 601-612.	0.6	23
99	What next for newly diagnosed glioblastoma?. <i>Future Oncology</i> , 2015, 11, 3273-3283.	1.1	22
100	Incorporation of Biomarker Assessment in Novel Clinical Trial Designs: Personalizing Brain Tumor Treatments. <i>Current Oncology Reports</i> , 2011, 13, 42-49.	1.8	21
101	Medical Management of High-Grade Astrocytoma: Current and Emerging Therapies. <i>Seminars in Oncology</i> , 2014, 41, 511-522.	0.8	21
102	ATIM-14. ALLIANCE A071101: A PHASE II RANDOMIZED TRIAL COMPARING THE EFFICACY OF HEAT SHOCK PROTEIN PEPTIDE COMPLEX-96 (HSPPC-96) VACCINE GIVEN WITH BEVACIZUMAB VERSUS BEVACIZUMAB ALONE IN THE TREATMENT OF SURGICALLY RESECTABLE RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi29-vi29.	0.6	21
103	Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas. <i>Journal of Neurosurgery</i> , 2000, 93, 201-207.	0.9	20
104	Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. <i>Investigational New Drugs</i> , 2005, 23, 495-503.	1.2	20
105	Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 85-90.	2.0	19
106	Chemotherapy of brain tumors. <i>Current Opinion in Neurology</i> , 2000, 13, 619-625.	1.8	18
107	Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. <i>Journal of Gene Medicine</i> , 2004, 6, 1216-1227.	1.4	18
108	Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN $\alpha$ 38 exposure. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 1303-1312.	1.0	18

#	ARTICLE	IF	CITATIONS
109	INNV-33. BARRIERS TO ACCRUAL AND ENROLLMENT IN BRAIN TUMOR TRIALS. <i>Neuro-Oncology</i> , 2019, 21, vi137-vi137.	0.6	18
110	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	3.2	18
111	PARP Inhibitors in Glioma: A Review of Therapeutic Opportunities. <i>Cancers</i> , 2022, 14, 1003.	1.7	18
112	Converting Tumor-specific Markers Into Reporters of Oncolytic Virus Infection. <i>Molecular Therapy</i> , 2009, 17, 1395-1403.	3.7	17
113	MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. <i>Molecular Oncology</i> , 2016, 10, 1387-1403.	2.1	17
114	Oncolytic Measles Virus Retargeting by Ligand Display. <i>Methods in Molecular Biology</i> , 2012, 797, 141-162.	0.4	17
115	Development of monoclonal antibody-based immunoassays for detection of <i>Helicobacter pylori</i> neutrophil-activating protein. <i>Journal of Immunological Methods</i> , 2012, 384, 1-9.	0.6	12
116	Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells. <i>Virus Research</i> , 2013, 172, 15-23.	1.1	11
117	Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience. <i>Neuro-Oncology</i> , 2021, 23, 1252-1260.	0.6	11
118	Phase II NCCTG trial of RT-irradiation and adjuvant BCNU plus irinotecan for newly diagnosed GBM. <i>Journal of Neuro-Oncology</i> , 2010, 99, 73-80.	1.4	8
119	Technology evaluation: Allovectin-7, Vical. <i>Current Opinion in Molecular Therapeutics</i> , 2002, 4, 80-7.	2.8	8
120	Where size matters: imaging-based biomarkers for patient stratification. <i>Neuro-Oncology</i> , 2017, 19, 7-8.	0.6	7
121	Interferon signaling predicts response to oncolytic virotherapy. <i>Oncotarget</i> , 2019, 10, 1544-1545.	0.8	7
122	Live Attenuated Measles Virus Vaccine Expressing <i>Helicobacter pylori</i> Heat Shock Protein A. <i>Molecular Therapy - Oncolytics</i> , 2020, 19, 136-148.	2.0	6
123	The Alliance AMBUSH Trial: Rationale and Design. <i>Cancers</i> , 2022, 14, 414.	1.7	5
124	Virotherapy for Brain Tumors – Defining the Path to Success. <i>New England Journal of Medicine</i> , 2022, 386, 2520-2522.	13.9	5
125	Translational research in oncolytic measles virotherapy: early discoveries and future steps. <i>Future Microbiology</i> , 2011, 6, 125-128.	1.0	3
126	Integrating Genomics Into Neuro-Oncology Clinical Trials and Practice. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 148-157.	1.8	2



#	ARTICLE	IF	CITATIONS
127	Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma. Hematology/Oncology Clinics of North America, 2021, 36, 113-132.	0.9	2
128	Phase I/randomized phase II trial of TRC105 plus bevacizumab versus bevacizumab in recurrent glioblastoma: North Central Cancer Treatment Group N1174 (Alliance). Neuro-Oncology Advances, 2022, 4, .	0.4	2
129	Examiner accuracy in cognitive testing in multisite brain-tumor clinical trials: an analysis from the Alliance for Clinical Trials in Oncology. Neuro-Oncology Practice, 2019, 6, 283-288.	1.0	1
130	Response to Letter to Editor. Neuro-Oncology, 2020, 22, 1706-1707.	0.6	1
131	Parameters of immunoglobulin extraction from dried blood spot cards and immunoassays for detection of antibody response to pathogens including the novel SARS-CoV-2. Journal of Immunological Methods, 2021, 492, 112996.	0.6	1
132	Measles virotherapy in prostate cancer treatment: a novel antitumor approach. Future Virology, 2009, 4, 203-207.	0.9	0